Centchroman Regress Mastalgia and Fibroadenoma: An Institutional Study

Sharma, Bhupender Kumar

doi:10.18535/jmscr/v4i7.25

Cited by 2 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study conducted by Bhupendra sharma, it was observed that the VAS scores in mastalgia patients were reduced to less than or equal to 3. [ 11 ] There results are in unison with our study. Ormeloxifene is a novel non-steroidal, selective antiestrogen(SERM)which has been used for the treatment of mastalgia and multiple small fibroadenomas.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Evaluating the Effect of Ormeloxifene on Multiple Fibroadenomas and Mastalgia

Brahmachari

Bhagat

Patil

et al. 2021

Journal of Pharmacy and Bioallied Sciences

View full text Add to dashboard Cite

Introduction: Most common benign breast conditions presenting in the breast clinics include fibroadenomas and mastalgia, both these conditions cause considerable anxiety in the patients. Among other treatment modalities, the hormonal drug treatments are gaining popularity. Ormeloxifene (centchroman) is an antiestrogenic drug which is shown to have effect in reducing the pain in mastalgia patients and the size of fibroadenoma. Objectives: Ormeloxifene is selective antiestrogen and a nonsteroidal drug. It has a discerning antiestrogen action and hence is useful for the treatment of mastalgia and multiple small fibroadenomas. Hence, the objective of our study was to assess the effect of Ormeloxifene (centchroman) on multiple fibroadenoma and mastalgia. Materials and Methods: Patients with benign breast disease attending our surgery outpatient department from June 2016 to July 2017. Patients were started on Ormeloxifene 30 mg on alternate days for a period of 3 months. Patients were followed up to 6 months after the inception of the study. Parameters recorded include the Visual Analog Scale (VAS) for pain and ultrasonography for breast lump size. Results: Thirty patients were included in the study. We found very good response in the mastalgia; the VAS scores in these patients dropped from 10 to 3 in 90% in the 1st week of introduction of the drug, and at the end of 1 month, almost all of the patients were painless. Overall final response was noted in terms of complete dissolution and change in the size was noted in 34% partial response in 46 %, no changes in 17 % and increase in size of fibroadenoma was noted in only one case. Conclusion: Novex is proved to be safe drug for the treatment of mastalgia and fibroadenoma. Its results were great in mastalgia group. At the end of 6 months, the number of surgeries (if needed) decrease and there is considerable improvement in the patient satisfaction rate.

show abstract

Section: Discussionsupporting

confidence: 90%

“…Centchroman does not have any side effects on endocrine system, liver and lipid function, and no serious complications such as heart attack, stroke, or thrombosis are associated with it. [ 10 11 ]…”

Section: Discussionmentioning

confidence: 99%

Evaluating the Effect of Ormeloxifene on Multiple Fibroadenomas and Mastalgia

Brahmachari

Bhagat

Patil

et al. 2021

Journal of Pharmacy and Bioallied Sciences

View full text Add to dashboard Cite

show abstract

“…In the studies similar to ours, a significance decrease has been observed in the size of fibroadenoma when Centchroman was given on daily or alternate regime. [21][22][23][24][25][26] Comparing the data of all these studies it is observed that daily dose schedule of Centchroman therapy was associated with better results as compared to when it was administered on alternate day regimen.…”

Section: Discussionmentioning

confidence: 99%

“…This has been evidenced by a great number of studies. [21][22][23][24][25] In addition, Gupta et al observed allergic rash as a side effect of Centchroman. 23 According to another study, there are concerns about this drug causing urinary incontinence and uterine prolapse.…”

Section: Discussionmentioning

confidence: 99%

A prospective study on the role of centchroman in regression of fibroadenoma

et al. 2021

View full text Add to dashboard Cite

Background: Fibroadenoma commonly present as painless breast lump in young girls. Nearly 10-15% regress spontaneously over the period of 6-60 months, rest are managed surgically. Centchroman (Saheli), a novel non-steroidal, selective anti-estrogen has been used for the treatment of mastalgia and its effectiveness in the treatment of fibroadenoma is being tested in the ongoing trials. Methods: A total of 60 patients between 15-35 years of age with painless lump breast of size 2 to 5 centimeters confirmed as fibroadenoma by fine needle aspiration cytology (FNAC) were included in the study. Detailed patient's characteristics, clinical history, physical examination (for size in 2 dimensions), ultrasound findings (for size in 3 dimensions) were assessed. All participants included in the study were given tablet Centchroman (Saheli) 30 mg thrice weekly orally for 3 months. Size of Fibroadenoma was reassessed clinically for size in two dimensions and ultrasonologically for size in three dimensions at 4 weeks and 3 months of starting of therapy.Results: Out of 60 patients, 18 patients (30%) had complete response, 40 patients (66.66%) showed a decrease in the size of fibroadenoma and only 2 patients (3.33%) had no response to this therapy. None showed an increase in size.Conclusions: It may prove to be the most effective modality for the treatment of small sized fibroadenoma breast especially in unmarried girls with minimal side effects. Ultrasonology may be relied upon for follow up measurements since it is more accurate in measuring the dimensions.

show abstract

Centchroman Regress Mastalgia and Fibroadenoma: An Institutional Study

Cited by 2 publications

References 12 publications

Evaluating the Effect of Ormeloxifene on Multiple Fibroadenomas and Mastalgia

Evaluating the Effect of Ormeloxifene on Multiple Fibroadenomas and Mastalgia

A prospective study on the role of centchroman in regression of fibroadenoma

Contact Info

Product

Resources

About